ADT-010 / Takeda - LARVOL DELTA

ADT-010, a novel immunomodulatory antibody that harnesses the anti-tumor properties of tissue-resident Vδ1 γδ T cells (AACR 2022) - "Despite recent advances in immune therapies in oncology, there currently remains a significant unmet need for effective and safe treatments for solid tumours. The challenges of treating such tumours which include infiltration into the tumour tissue and discrimination between healthy and tumour cells have the potential to be addressed by novel approaches such as Adaptate’s ADT-010 antibody. ADT-010 specifically activates a population of tumour-resident Vδ1 T cells that can then orchestrate a potent and highly selective anti-tumour response through direct killing.Adaptate’s first-in-class ADT-010 is being progressed to the clinic for the treatment of solid tumour indications."

Oncology • Solid Tumor • IL2RA • LAMP1

Second Abingworth gamma delta T cell company, Adaptate Biotherapeutics, to be acquired by Takeda (PRNewswire) - "Abingworth...announces its portfolio company Adaptate Biotherapeutics is to be acquired by Takeda Pharmaceutical Company Limited for a pre-negotiated upfront payment....Through the acquisition, Takeda will acquire Adaptate's antibody-based γδ T-cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate's γδ T-cell engagers are engineered to specifically activate γδ T cell-mediated immune responses at tumour sites while sparing damage to healthy cells."

M&A • Oncology